updated 1/14/2010 4:42:44 PM ET 2010-01-14T21:42:44

Federal health regulators said Thursday that recent data do not show a connection between a popular inhaler and previously reported risks of stroke, heart attack and death.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

The Spiriva HandiHaler is made by German drugmaker Boehringer Ingelheim and co-marketed in the U.S. with Pfizer. The device uses tiny drug capsules and an inhalation tube to treat chronic obstructive pulmonary disease, which causes coughing, wheezing and shortness of breath.

The FDA began investigating Spiriva's safety last March after Boehringer reported slightly higher rates of stroke and heart attack for patients using its device, compared with a placebo.

The FDA now says a recent review of a company-sponsored, 6,000-patient study did not show evidence of increased risk. In November, an FDA panel of outside experts voted that the same study resolved safety concerns over Spiriva.

Since then, the FDA approved stronger labeling claims on the device about its ability to fight symptoms of lung disease.

Pfizer said in a statement that it welcomed the FDA's conclusion.

"This reaffirms the well-established safety profile of Spiriva Handihaler," the company said.

Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments